BR112019005351A2 - terapia combinada com agonistas de cnp de liberação controlada - Google Patents
terapia combinada com agonistas de cnp de liberação controladaInfo
- Publication number
- BR112019005351A2 BR112019005351A2 BR112019005351A BR112019005351A BR112019005351A2 BR 112019005351 A2 BR112019005351 A2 BR 112019005351A2 BR 112019005351 A BR112019005351 A BR 112019005351A BR 112019005351 A BR112019005351 A BR 112019005351A BR 112019005351 A2 BR112019005351 A2 BR 112019005351A2
- Authority
- BR
- Brazil
- Prior art keywords
- controlled release
- combination therapy
- release cnp
- growth stimulation
- cnp agonists
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title abstract 4
- 238000013270 controlled release Methods 0.000 title abstract 2
- 238000002648 combination therapy Methods 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 abstract 3
- 230000000638 stimulation Effects 0.000 abstract 3
- 229940079593 drug Drugs 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2242—Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
a presente invenção refere-se a uma combinação de um agonista de cnp e pelo menos uma outra porção biologicamente ativa ou fármaco para uso em um método para o tratamento ou prevenção de transtornos que se beneficiam da estimulação de crescimento, composições farmacêuticas que compreendem pelo menos um agonista de cnp, de preferência um agonista de cnp de liberação controlada, em que a composição farmacêutica compreende pelo menos uma outra porção biologicamente ativa ou fármaco, ao uso destas composições farmacêuticas como um medicamento, ao seu uso no tratamento de transtornos que se beneficiam da estimulação de crescimento e a métodos de prevenção ou tratamento de um paciente que tem um transtorno que se beneficia da estimulação de crescimento.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP16191456 | 2016-09-29 | ||
PCT/EP2017/074596 WO2018060314A1 (en) | 2016-09-29 | 2017-09-28 | Combination therapy with controlled-release cnp agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019005351A2 true BR112019005351A2 (pt) | 2019-06-11 |
Family
ID=57047055
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019005351A BR112019005351A2 (pt) | 2016-09-29 | 2017-09-28 | terapia combinada com agonistas de cnp de liberação controlada |
Country Status (26)
Country | Link |
---|---|
US (2) | US11564974B2 (pt) |
EP (2) | EP3518930B1 (pt) |
JP (1) | JP7189133B2 (pt) |
KR (2) | KR20230066147A (pt) |
CN (1) | CN109843295B (pt) |
AU (2) | AU2017336253B2 (pt) |
BR (1) | BR112019005351A2 (pt) |
CA (1) | CA3037448A1 (pt) |
DK (1) | DK3518930T3 (pt) |
ES (1) | ES2943013T3 (pt) |
FI (1) | FI3518930T3 (pt) |
HR (1) | HRP20230385T1 (pt) |
HU (1) | HUE062117T2 (pt) |
IL (3) | IL305975A (pt) |
LT (1) | LT3518930T (pt) |
MA (1) | MA46430B1 (pt) |
MX (1) | MX2019003173A (pt) |
NZ (1) | NZ751746A (pt) |
PL (1) | PL3518930T3 (pt) |
PT (1) | PT3518930T (pt) |
RS (1) | RS64203B1 (pt) |
RU (1) | RU2768747C2 (pt) |
SG (2) | SG10202111952PA (pt) |
SI (1) | SI3518930T1 (pt) |
WO (1) | WO2018060314A1 (pt) |
ZA (1) | ZA201901810B (pt) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
AU2017205268B2 (en) * | 2016-01-08 | 2022-02-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
KR102373744B1 (ko) | 2016-01-08 | 2022-03-15 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
IL259658B1 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with reduced side effects |
IL301616A (en) | 2016-03-01 | 2023-05-01 | Ascendis Pharma Bone Diseases As | PTH medications |
PL3518960T3 (pl) | 2016-09-29 | 2023-12-27 | Ascendis Pharma Bone Diseases A/S | Schemat dawkowania związku pth o kontrolowanym uwalnianiu |
DK3518961T3 (da) | 2016-09-29 | 2023-04-24 | Ascendis Pharma Bone Diseases As | PTH-forbindelser med lave forhold mellem top og bund |
US11564974B2 (en) | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
Family Cites Families (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0892789B2 (en) | 1996-04-12 | 2009-11-18 | Warner-Lambert Company LLC | Irreversible inhibitors of tyrosine kinases |
WO1999007701A1 (en) | 1997-08-05 | 1999-02-18 | Sugen, Inc. | Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors |
US6624142B2 (en) | 1997-12-30 | 2003-09-23 | Enzon, Inc. | Trimethyl lock based tetrapartate prodrugs |
CN1169573C (zh) | 1998-09-28 | 2004-10-06 | 参天制药株式会社 | 用于治疗角结膜障碍的、包含作为活性组分的钠尿肽的泪液分泌促进剂或滴眼剂 |
JP4252746B2 (ja) * | 2001-10-05 | 2009-04-08 | 一和 中尾 | 軟骨無形成症治療剤 |
BRPI0203172B8 (pt) * | 2001-09-28 | 2021-05-25 | Nakao Kazuwa | composição farmacêutica para acondroplasia |
EP2292271A3 (en) | 2001-10-10 | 2011-09-14 | BioGeneriX AG | Remodelling and glycoconjugation of an antibody |
US7054679B2 (en) | 2001-10-31 | 2006-05-30 | Robert Hirsh | Non-invasive method and device to monitor cardiac parameters |
US7122189B2 (en) | 2002-08-13 | 2006-10-17 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
CA2504287A1 (en) | 2002-11-26 | 2004-06-10 | Nobex Corporation | Natriuretic compounds, conjugates, and uses thereof |
US7332164B2 (en) | 2003-03-21 | 2008-02-19 | Enzon Pharmaceuticals, Inc. | Heterobifunctional polymeric bioconjugates |
ES2512499T3 (es) | 2003-04-08 | 2014-10-24 | Yeda Research And Development Co., Ltd. | Fármacos pegilados reversibles |
US7690003B2 (en) | 2003-08-29 | 2010-03-30 | Fuller Jeffrey C | System and method for increasing data throughput using thread scheduling |
EP2932981B1 (en) | 2003-09-19 | 2021-06-16 | Novo Nordisk A/S | Albumin-binding derivatives of GLP-1 |
DK1732607T3 (da) | 2004-03-23 | 2019-07-22 | Ascendis Pharma Gmbh | Polymer-prodrug med en selvofrende linker |
US7968085B2 (en) | 2004-07-05 | 2011-06-28 | Ascendis Pharma A/S | Hydrogel formulations |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
CU23556A1 (es) | 2005-11-30 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Estructura polimérica semejante a dendrímero para la obtención de conjugados de interés farmacéutico |
US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
JP2010502231A (ja) | 2006-09-08 | 2010-01-28 | メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ | 血管拡張作用を欠く水利尿およびナトリウム利尿ポリペプチド |
KR20090055623A (ko) | 2006-09-15 | 2009-06-02 | 엔존 파마슈티컬즈, 인코포레이티드 | 올리고뉴클레오티드 전달을 위한 방해된 에스테르 기재 생분해성 링커 |
KR20090082447A (ko) | 2006-11-09 | 2009-07-30 | 알콘 리서치, 리미티드 | 약물 전달용 수불용성 폴리머 매트릭스 |
KR20080098216A (ko) * | 2007-05-04 | 2008-11-07 | 한미약품 주식회사 | 캐리어 물질을 이용한 나트륨 배설 펩타이드 약물 결합체 |
DE602008005596D1 (de) | 2007-06-21 | 2011-04-28 | Univ Muenchen Tech | Biologisch aktive proteine mit erhöhter in-vivo- und/oder in-vitro-stabilität |
JP2010533202A (ja) | 2007-07-11 | 2010-10-21 | エンゾン ファーマシューティカルズ,インコーポレーテッド | 多置換芳香族部分を含むポリマー性薬剤送達システム |
WO2009067639A2 (en) | 2007-11-21 | 2009-05-28 | Biomarin Pharmaceutical Inc. | Variants of c-type natriuretic peptide |
DK2237799T3 (da) | 2008-02-01 | 2019-06-11 | Ascendis Pharma As | Prodrug omfattende en selv-spaltbar linker |
CA2723263A1 (en) | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
WO2009156481A1 (en) | 2008-06-25 | 2009-12-30 | Ascendis Pharma As | Pegylated bnp |
WO2010033217A1 (en) | 2008-09-19 | 2010-03-25 | Nektar Therapeutics | Polymer conjugates of cd-np peptides |
MX362028B (es) | 2009-02-03 | 2019-01-04 | Amunix Pharmaceuticals Inc | Polipeptidos recombinantes extendidos y composiciones que comprenden los mismos. |
DK3175863T3 (da) * | 2009-05-20 | 2022-02-07 | Biomarin Pharm Inc | Varianter af c-type natriuretisk peptid |
CA2769162C (en) | 2009-07-31 | 2017-12-05 | Ascendis Pharma As | Biodegradable polyethylene glycol based water-insoluble hydrogels |
US9173953B2 (en) | 2009-07-31 | 2015-11-03 | Ascendis Pharma As | Prodrugs containing an aromatic amine connected by an amido bond to a linker |
WO2011031441A1 (en) | 2009-08-28 | 2011-03-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Therapy with a chimeric molecule and a pro-apoptotic agent |
WO2011075471A2 (en) | 2009-12-18 | 2011-06-23 | Alcon Research, Ltd. | Novel npr-b agonists and methods of use for the treatment of c-type natriuretic peptide-mediated disorders |
WO2011082368A2 (en) | 2009-12-31 | 2011-07-07 | Enzon Pharmaceuticals, Inc | Polymeric conjugates of aromatic amine containing compounds including releasable urea linker |
EP2525829A1 (en) | 2010-01-22 | 2012-11-28 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
EP2525831B1 (en) | 2010-01-22 | 2019-05-15 | Ascendis Pharma A/S | Carrier-linked carbamate prodrug linkers |
EP2525830B1 (en) | 2010-01-22 | 2016-05-11 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
EP2552967A4 (en) | 2010-04-02 | 2014-10-08 | Amunix Operating Inc | BINDING FUSION PROTEINS, BINDING FUSION PROTEIN MEDICINAL CONJUGATES, XTEN MEDICAMENT CONJUGATES, AND METHOD FOR THEIR PREPARATION AND USE |
WO2011140393A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled release from macromolecular conjugates |
WO2011140392A1 (en) | 2010-05-05 | 2011-11-10 | Prolynx Llc | Controlled drug release from solid supports |
MX357674B (es) | 2010-05-21 | 2018-07-18 | Xl Protein Gmbh | Polipeptidos biosinteticos de espira aleatoria de prolina/alanina y sus usos. |
WO2012002047A1 (ja) | 2010-06-30 | 2012-01-05 | Necソフト株式会社 | 属性判定方法、属性判定装置、プログラム、記録媒体および属性判定システム |
US20140323402A1 (en) | 2011-08-12 | 2014-10-30 | Ascendis Phama A/S | Protein Carrier-Linked Prodrugs |
AU2012296949B2 (en) | 2011-08-12 | 2016-09-15 | Ascendis Pharma A/S | High-loading water-soluble carrier-linked prodrugs |
IN2014CN00989A (pt) | 2011-08-12 | 2015-04-10 | Ascendis Pharma As | |
WO2013024048A1 (en) | 2011-08-12 | 2013-02-21 | Ascendis Pharma A/S | Polymeric hyperbranched carrier-linked prodrugs |
AU2012296955B2 (en) | 2011-08-12 | 2016-12-15 | Ascendis Pharma A/S | Carrier-linked prodrugs having reversible carboxylic ester linkages |
WO2013036857A1 (en) | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
AU2013254756B2 (en) | 2012-04-25 | 2017-03-30 | Ascendis Pharma A/S | Prodrugs of hydroxyl-comprising drugs |
CN104379171A (zh) | 2012-04-25 | 2015-02-25 | 第一三共株式会社 | 骨修复促进剂 |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
RU2647729C2 (ru) | 2012-10-11 | 2018-03-19 | Асцендис Фарма Ас | Пролекарства на основе гидрогеля |
WO2014060512A1 (en) | 2012-10-17 | 2014-04-24 | Novo Nordisk Health Care Ag | Fatty acid acylated amino acids for growth hormone delivery |
JP6536871B2 (ja) * | 2013-12-02 | 2019-07-03 | 国立大学法人京都大学 | Fgfr3病の予防および治療剤ならびにそのスクリーニング方法 |
CN106232141A (zh) * | 2014-02-27 | 2016-12-14 | 第三共株式会社 | 针对由给予类固醇诱发的生长不足的药物 |
DK3653227T5 (da) | 2014-11-18 | 2023-08-21 | Ascendis Pharma Endocrinology Div A/S | Hidtil ukendte polymere hgh-prodrugs |
WO2016110577A1 (en) | 2015-01-09 | 2016-07-14 | Ascendis Pharma A/S | Cnp prodrugs |
HUE057083T2 (hu) | 2015-12-08 | 2022-04-28 | Biomarin Pharm Inc | C-típusú nátriuretikus peptid változatainak alkalmazása oszteoartritisz kezelésére |
KR102373744B1 (ko) | 2016-01-08 | 2022-03-15 | 아센디스 파마 그로우쓰 디스오더스 에이/에스 | 낮은 npr-c 결합을 갖는 제어 방출성 cnp 작용제 |
AU2017205268B2 (en) | 2016-01-08 | 2022-02-17 | Ascendis Pharma Growth Disorders A/S | CNP prodrugs with large carrier moieties |
IL259658B1 (en) | 2016-01-08 | 2024-02-01 | Ascendis Pharma Growth Disorders As | Controlled-release CNP agonists with reduced side effects |
NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
BR112018011152A2 (pt) | 2016-01-08 | 2018-11-21 | Ascendis Pharma Growth Disorders As | agonistas de cnp de liberação controlada com estabilidade em nep aumentada |
LT3400019T (lt) | 2016-01-08 | 2022-12-12 | Ascendis Pharma Growth Disorders A/S | Cnp provaistai su prie žiedo fragmento prijungtu nešikliu |
IL301616A (en) | 2016-03-01 | 2023-05-01 | Ascendis Pharma Bone Diseases As | PTH medications |
US11564974B2 (en) | 2016-09-29 | 2023-01-31 | Ascendis Pharma Growth Disorders A/S | Combination therapy with controlled-release CNP agonists |
CN112638388A (zh) | 2018-08-16 | 2021-04-09 | 大连万春布林医药有限公司 | 刺激免疫反应的方法和组合物 |
JP2022520193A (ja) | 2019-02-11 | 2022-03-29 | アセンディス ファーマ グロース ディスオーダーズ エー/エス | Cnpコンジュゲートの乾燥医薬製剤 |
-
2017
- 2017-09-28 US US16/338,185 patent/US11564974B2/en active Active
- 2017-09-28 FI FIEP17781429.0T patent/FI3518930T3/fi active
- 2017-09-28 LT LTEPPCT/EP2017/074596T patent/LT3518930T/lt unknown
- 2017-09-28 NZ NZ751746A patent/NZ751746A/en unknown
- 2017-09-28 MX MX2019003173A patent/MX2019003173A/es unknown
- 2017-09-28 JP JP2019516647A patent/JP7189133B2/ja active Active
- 2017-09-28 BR BR112019005351A patent/BR112019005351A2/pt unknown
- 2017-09-28 AU AU2017336253A patent/AU2017336253B2/en active Active
- 2017-09-28 RS RS20230385A patent/RS64203B1/sr unknown
- 2017-09-28 EP EP17781429.0A patent/EP3518930B1/en active Active
- 2017-09-28 WO PCT/EP2017/074596 patent/WO2018060314A1/en unknown
- 2017-09-28 DK DK17781429.0T patent/DK3518930T3/da active
- 2017-09-28 EP EP23159718.8A patent/EP4223309A1/en active Pending
- 2017-09-28 HR HRP20230385TT patent/HRP20230385T1/hr unknown
- 2017-09-28 CN CN201780058524.8A patent/CN109843295B/zh active Active
- 2017-09-28 KR KR1020237015410A patent/KR20230066147A/ko not_active Application Discontinuation
- 2017-09-28 KR KR1020197012470A patent/KR102531327B1/ko active IP Right Grant
- 2017-09-28 HU HUE17781429A patent/HUE062117T2/hu unknown
- 2017-09-28 SG SG10202111952PA patent/SG10202111952PA/en unknown
- 2017-09-28 CA CA3037448A patent/CA3037448A1/en active Pending
- 2017-09-28 IL IL305975A patent/IL305975A/en unknown
- 2017-09-28 RU RU2019112897A patent/RU2768747C2/ru active
- 2017-09-28 IL IL290054A patent/IL290054B2/en unknown
- 2017-09-28 SG SG11201901534VA patent/SG11201901534VA/en unknown
- 2017-09-28 PL PL17781429.0T patent/PL3518930T3/pl unknown
- 2017-09-28 PT PT177814290T patent/PT3518930T/pt unknown
- 2017-09-28 MA MA46430A patent/MA46430B1/fr unknown
- 2017-09-28 ES ES17781429T patent/ES2943013T3/es active Active
- 2017-09-28 SI SI201731339T patent/SI3518930T1/sl unknown
-
2019
- 2019-03-25 ZA ZA2019/01810A patent/ZA201901810B/en unknown
- 2019-03-25 IL IL265592A patent/IL265592B/en unknown
-
2022
- 2022-12-22 US US18/145,676 patent/US20230302091A1/en active Pending
-
2023
- 2023-03-20 AU AU2023201709A patent/AU2023201709A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
PH12019502058A1 (en) | Farnesoid x receptor agonists and uses thereof | |
BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
BR112015030377A2 (pt) | preparação compreendendo pelo menos um quimioterápico ou substância citotóxica para uso no tratamento de uma doença de um paciente mamífero, preparação e método para tratamento de câncer em um paciente mamífero através de terapia de radiação | |
BR112018004532A2 (pt) | uso de akkermansia pasteurizado para o tratamento de distúrbios metabólicos | |
BR112013018920A2 (pt) | composições de nanopartículas, formulações destas e seus usos | |
BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
BR112019008431A2 (pt) | aplicação de (s)-norcetamina e sal da mesma como fármaco | |
BR112015027282A8 (pt) | formulação líquida e kit compreendendo fenfluramina, e usos da mesma no tratamento de síndrome de dravet | |
MX2016011975A (es) | Metodos para reducir el riesgo cardiovascular. | |
BR112014016672A8 (pt) | compostos de carbamato, seu uso e composição farmaceuticamente aceitável os compreendendo | |
AR105712A1 (es) | Composiciones de insulina de rápida acción | |
BR112015006093A2 (pt) | combinação de rasagilina e pridopidine para o tratamento de desordens neurodegenerativas, particularmente na doença de huntington | |
MX2017017138A (es) | Conjugados homogeneos especificos de sitio con inhibidores de ksp. | |
PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
MX2017006938A (es) | Terapia de combinacion para el tratamiento de cancer. | |
BR112017009798A2 (pt) | profármacos de hgh poliméricos | |
MX2015012559A (es) | Novedosos fármacos de alta penetración y sus composiciones para el tratamiento de enfermedades de parkinson. | |
BR112018011607A2 (pt) | composto, composição farmacêutica, métodos para tratamento de um distúrbio relacionado ao estrogênio e de um câncer, para fabricação de um medicamento para uso terapêutico no tratamento de um distúrbio e para prevenção de um distúrbio relacionado ao estrogênio, uso de um composto ou de uma composição farmacêutica, e, processo para preparação de um produto farmacêutico. | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112017006113A8 (pt) | usos de auristatina, composições farmacêuticas, formas de dosagem para o tratamento de câncer e kits. | |
BR112015026247A2 (pt) | métodos para o tratamento de câncer com o uso de terapia combinada com inibidor de cinase tor | |
BR112015019802A2 (pt) | formulações farmacêuticas de nitrito e usos das mesmas | |
BR112018012765A2 (pt) | composição, método para tratamento, prevenção e/ou melhora de uma afecção médica, e, dispositivo mecânico. | |
BR112018071972A2 (pt) | métodos para tratamento ou prevenção de uma doença ou distúrbio de fígado, para tratamento de câncer de fígado e para tratamento de inflamação no fígado, trato biliar ou pâncreas de um animal, alfa-defensina e/ou ss-defensina de mamífero e/ou uma catelicidina e/ou um análogo de glp-1, e, uso dos mesmos. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |